Compositions and methods for the reduction or treatment of fibrosis
AssigneeAxcella Health Inc.
InventorsMichael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, Luke S. Hamm, Svetlana Marukian, Nadine Daou
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions and methods for reducing or treating fibrosis, e.g., in a subject having a fibrotic condition or disorder.
Claims22
A method for reducing fibrosis in a subject, comprising administering to the subject in need thereof an effective amount of a composition comprising:
- a) a leucine amino acid entity,
- b) an arginine amino acid entity,
- c) glutamine amino acid entity;
- and
- d) a N-acetylcysteine (NAC)-entity;
- provided that:
- the fibrosis is not liver fibrosis,
- thereby reducing the fibrosis in the subject.
A method of treating a fibrotic condition or disorder in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising:
- a) a leucine-amino acid entity
- b) an arginine-amino acid entity,
- c) glutamine-amino acid entity;
- and
- d) NAC-entity;
- provided that:
- the fibrotic condition or disorder is not a liver fibrotic condition or disorder,
- thereby treating the fibrotic condition or disorder.
A composition for use in reducing fibrosis in a subject, comprising an effective amount of a composition comprising:
- a) a leucine amino acid entity,
- b) an arginine amino acid entity,
- c) glutamine amino acid entity;
- and
- d) a N-acetylcysteine (NAC)-entity;
- provided that:
- the fibrosis is not liver fibrosis.
A composition for use in intreating a fibrotic condition or disorder in a subject in need thereof, comprising an effective amount of a composition comprising:
- a) a leucine-amino acid entity
- b) an arginine-amino acid entity,
- c) glutamine-amino acid entity;
- and
- d) NAC-entity;
- provided that:
- the fibrotic condition or disorder is not a liver fibrotic condition or disorder.
Dependencies are inferred from the claim text.